Log in or Sign up for Free to view tailored content for your specialty!
Hepatitis C News
National HCV elimination program a ‘golden opportunity’ to improve lives
WASHINGTON — In this video, John Ward, MD, director of the Coalition for Global Hepatitis Elimination at the CDC Taskforce for Global Health, discusses the need for a national commitment to a hepatitis C elimination program.
‘No one should be dying’ of HCV with currently available diagnostics, treatment
WASHINGTON — In this video, John Ward, MD, director of the Coalition for Global Hepatitis Elimination at the CDC Taskforce for Global Health, discusses successes and challenges in hepatitis elimination at The Liver Meeting.
Log in or Sign up for Free to view tailored content for your specialty!
Patient participation at The Liver Meeting ‘invaluable’ for other patients, providers
WASHINGTON — In this video, Tatyana Kushner, MD, associate professor in the division of liver diseases at the Icahn School of Medicine at Mount Sinai, discusses the benefits of patient inclusion and participation at The Liver Meeting.
Pregnant people ‘the last frontier’ of treatment in HCV
WASHINGTON — Although well-established and effective treatment protocols exist for most patients with hepatitis C virus infection, a presenter at The Liver Meeting said uncertainty remains when treating pregnant people with HCV.
Among barriers to HCV care, the ‘real challenge’ is getting treatment to patients in need
WASHINGTON — A special interest group session at The Liver Meeting focused on challenges in treating patients with hepatitis C virus, as well as disparities in access to care.
Despite setbacks, experts have hope for HCV elimination
WASHINGTON — A number of presentations, lectures and posters at The Liver Meeting focused on hepatitis C virus and work being done to achieve the WHO goal for elimination by 2030, according to an expert in attendance.
Recent injection drug use linked to HCV reinfection after DAA treatment
WASHINGTON — The risk for hepatitis C virus reinfection after direct-acting antiviral therapy was high in people with recent injection drug use, while antipsychotic drugs and opioid agonists offered possible protective effects.
HCV care must ‘move away from the ivory tower’ to achieve elimination
WASHINGTON — A decentralized, integrated care model is necessary to eradicate hepatitis C virus in hard-to-reach populations, including among individuals who use drugs, according to a presenter at The Liver Meeting.
Ramping up HCV elimination tactics could save 90,000 lives, $60 billion by 2050
WASHINGTON — An accelerated, nationally organized plan to eliminate hepatitis C virus in the United States could save more than 90,000 lives and nearly $60 billion by 2050, according to a health economics expert at The Liver Meeting.
‘We need your help’: AASLD support, outreach key to success of HCV elimination program
WASHINGTON — An expert panel of physicians, researchers and scientific advisers called upon The Liver Meeting attendees to support a proposed national HCV elimination program in the US.
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read
-
Headline News
‘We have a home’: Physician aims to create network of women allergists
November 14, 20245 min read -
Headline News
Diversified portfolios allow for ‘smoother ride’
November 14, 20243 min read -
Headline News
Predelivery concussion linked to increased risk for severe maternal mental illness
November 12, 20242 min read